Importantly, NLK is upregulated selectively in affected neurons from patients with ALS and correlates with TDP43 mislocalization, implicating NLK as a key determinant of disease pathophysiology and highlighting NLK as a promising therapeutic target for ALS and related TDP43 proteinopathies. The gene discussed is TARDBP; the disease is proteostasis deficiencies.